Senseonics Holdings and Ascensia Diabetes Care are targeting the 2024 fourth quarter for launch of the world’s first 365-day continuous glucose monitoring system, Eversense 365.
Senseonics has been working to extend the wear life of its fully implantable Eversense glucose sensors since receiving PMA approval...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?